The Most Undervalued Healthcare Stock in the S&P 500 Right Now

Bristol Myers Squibb is trading at about 10x forward earnings and 9.9x trailing free cash flow while offering a dividend yield above 4%, making it one of the cheapest large-cap pharma stocks by valuation. Q1 2026 revenue rose 3% to $11.5 billion, with the growth portfolio up 12% to $6.2 billion and newer drugs such as Breyanzi, Camzyos, and Reblozyl posting strong growth. Management also expects about $2 billion in annual cost savings by 2027, partly offsetting patent-cliff pressure from Revlimid and eventually Eliquis.

Analysis

The market is treating BMY like a melting-ice-cube story, but the setup is more nuanced: the key question is not whether legacy products decline, but whether the growth portfolio can stay ahead of the cliff long enough for the balance sheet to do the heavy lifting. If management really delivers $2B of annual savings, that drops almost straight to operating leverage and can offset a meaningful share of patent drag, which matters more in a low-multiple name than in a growth stock. In other words, every incremental dollar of steady FCF expands the rerating potential because the market is already capitalizing BMY as if the franchise is structurally broken.

Second-order beneficiaries are the capital return cohort and value-biased healthcare allocators, not necessarily BMY alone. A sustained stabilization in BMY would pressure other large-cap pharma names trading on similar cliff narratives, especially if investors begin to differentiate between businesses with real pipeline replacement and those merely buying time with buybacks. Conversely, Pfizer is less exposed to this specific re-rating because its own post-COVID reset has already forced a different investor base and valuation regime.

The real catalyst window is 6-18 months: 2026 clinical/regulatory readouts plus evidence that growth drugs keep compounding while cost actions hit the P&L. The risk is that consensus is underestimating the slope of decline in the legacy assets; if the newer portfolio decelerates even modestly, the stock can stay trapped at a single-digit multiple despite appearing cheap. The contrarian miss is that BMY may not need aggressive top-line growth to work — it only needs to prove that normalized earnings are less fragile than the market assumes.

Key Decisions for Investors

• Long BMY vs. a basket of patent-cliff peers over the next 6-12 months; use a pair trade to isolate execution upside from sector beta. Risk/reward improves if growth portfolio revenue continues to stay above 50% of total sales.
• Buy BMY on weakness toward the low end of its recent range and pair with a short in a higher-multiple large-cap pharma name lacking near-term pipeline catalysts. The trade is for valuation convergence, not outright sector direction.
• Sell cash-secured puts in BMY 3-6 months out if implied volatility remains elevated; the thesis is that the market is overpaying for downside protection relative to the company’s FCF floor. Be prepared to own the stock if assigned.
• For event-driven traders, add BMY into 2026 catalyst windows only after pullbacks ahead of trial/regulatory updates. The upside is multiple expansion if one or two readouts validate pipeline replacement, while downside is likely capped by the dividend and cash generation.
• Avoid chasing the move after sharp outperformance in a single session; this is a slow-repricing story, and the best entry is when the market reasserts cliff fears on weak patent-expiration headlines.